James L Gulley MD Ph.D.

Genitourinary Oncology, Hematologic Oncology

Clinical Trials Group Center for Cancer Research National Cancer Institute

10 Rockville Pike# 8B08Bethesda, MD 20892
Phone+1 301-435-2956
Fax+1 301-480-5094

Dr. Gulley is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gulley's full profile Already have an account?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Emory University School of MedicineResidency, Internal Medicine, 1995 - 1998
Loma Linda University School of MedicineClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MD State Medical License 2001 - 2028
GA State Medical License 1996 - 2007

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2008-2013
Top Doctors:Baltimore Area Castle Connolly, 2012

Clinical Trials

Eligibility Screening for the NIH Intramural Research Program Clinical Protocols Start of enrollment: 2004 Jan 14
COMPLETED
Collection of Blood From Patients With Cancer Start of enrollment: 2002 Jul 16
RECRUITING
Sequential Vaccinations in Prostate Cancer Patients Start of enrollment: 2003 May 22
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.
Sigrid Dubois, Yetzali Claudio-Medina, Jennifer L Marte, James L Gulley, Juergen R Mueller
Oncoimmunology. 2026-12-31
Erratum to 'Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer' [JTO Clinical and Research Reports 7 (20...
Alisa K Sivapiromrat, Meredith J McAdams, Renee N Donahue, Carolina Celades, Wiem Lassoued
JTO Clinical and Research Reports. 2026-09-01
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer.
Brett A Schroeder, Chirayu Mohindroo, Anna-Lena Meinhardt, Nobuyuki Takahashi, Yang Zhang
Cancer Discovery. 2026-08-03

Journal Articles

Vaccines as an Integral Component of Cancer Immunotherapy
James Gulley, MD, JAMA

Abstracts/Posters

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies
James Gulley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatec...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
New Agents in Clinical Trials: Significant Phase I-III Clinical Trials. The Future of Immunotherapy: Novel Agents in Clinical Trials
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

FDA Approves Injectable Nivolumab, an Alternative to IV InfusionFebruary 19th, 2025
Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for Its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual MeetingNovember 10th, 2024
Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical OfficerMarch 1st, 2023

Grant Support

E7 TCR-T cell therapy for HPV-associated cancersRUTGERS BIOMEDICAL AND HEALTH SCIENCES2024–2028
Clinical Trials Employing Cancer Vaccine Combination TherapiesNational Cancer Institute2010–2011
Clinical Trials Employing Cancer Vaccine Combination TherapiesDivision Of Basic Sciences - Nci2009
Clinical Trials Employing Cancer Vaccine Combination TherapiesNational Cancer Institute2008
Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesNational Cancer Institute2008